Jill Roberts Center for Inflammatory Bowel Disease

You are here

Treatment of metastatic cutaneous Crohn disease with certolizumab.

TitleTreatment of metastatic cutaneous Crohn disease with certolizumab.
Publication TypeJournal Article
Year of Publication2015
AuthorsKiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H
JournalDermatol Online J
Volume21
Issue11
Date Published2015
ISSN1087-2108
Abstract

Metastatic Crohn disease is a rare cutaneous manifestation of Crohn disease characterized by granulomatous lesions discontinuous with the diseased areas of the gastrointestinal tract. We report a case of a 32-year-old woman with history of Crohn disease who was admitted for treatment of cellulitis after presenting with a tender erythematous plaque of the left calf. Microbiological tests including tissue cultures were negative. A skin biopsy revealed granulomatous dermatitis consistent with metastatic cutaneous Crohn disease. Owing to concomitant perianal fistulas and abscesses and prior infusion reaction to infliximab, the patient was treated with certolizumab, a pegylated tumor necrosis factor (TNF) inhibitor combined with methotrexate resulting in complete resolution of the skin lesion. This case emphasizes the importance of recognizing this rare skin manifestation of Crohn disease and adds certolizumab as one of TNF inhibitors useful in the treatment of metastatic cutaneous Crohn disease.

Alternate JournalDermatol. Online J.
PubMed ID26632928